Home › Compare › CGUD vs JNJ

CGUD vs JNJ: Dividend Comparison 2026

CGUD yields 250000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CGUD wins by $4.567699004441311e+30M in total portfolio value
10 years
CGUD
CGUD
● Live price
250000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.567699004441311e+30M
Annual income
$4,564,107,688,187,857,300,000,000,000,000,000,000.00
Full CGUD calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CGUD vs JNJ

📍 CGUD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCGUDJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CGUD + JNJ cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CGUD pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CGUD
Annual income on $10K today (after 15% tax)
$21,250,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,879,491,534,959,678,500,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, CGUD beats the other by $3,879,491,534,959,678,500,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CGUD + JNJ for your $10,000?

CGUD: 50%JNJ: 50%
100% JNJ50/50100% CGUD
Portfolio after 10yr
$2.2838495022206556e+30M
Annual income
$2,282,053,844,093,928,700,000,000,000,000,000,000.00/yr
Blended yield
99.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CGUD
No analyst data
Altman Z
-121.0
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CGUD buys
0
JNJ buys
0
No recent congressional trades found for CGUD or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCGUDJNJ
Forward yield250000.00% ✓2.13%
Annual dividend / share$2.00$5.20 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28% ✓
Portfolio after 10y$4.567699004441311e+30M$30.3K ✓
Annual income after 10y$4,564,107,688,187,857,300,000,000,000,000,000,000.00 ✓$4,689.40
Total dividends collected$4.567463897060879e+30M$15.4K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CGUD vs JNJ ($10,000, DRIP)

YearCGUD PortfolioCGUD Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$25,010,700$25,000,000.00$10,592$272.30+$25.00M → CGUD
2$58,462,976,402$58,436,214,953.27$11,289$357.73+$58462.97M → CGUD
3$127,722,124,784,416$127,659,569,399,665.92$12,123$472.89+$127722124.77M → CGUD
4$260,784,910,907,288,130$260,648,248,233,768,800.00$13,141$629.86+$260784910907.27M → CGUD
5$497,657,939,618,196,950,000$497,378,899,763,526,240,000.00$14,408$846.81+$497657939618196.94M → CGUD
6$887,590,576,640,622,200,000,000$887,058,082,645,230,600,000,000.00$16,021$1,151.60+$887590576640622208.00M → CGUD
7$1,479,547,418,610,237,200,000,000,000$1,478,597,696,693,231,600,000,000,000.00$18,122$1,588.22+$1.4795474186102372e+21M → CGUD
8$2,305,052,548,351,757,200,000,000,000,000$2,303,469,432,613,844,500,000,000,000,000.00$20,930$2,228.20+$2.3050525483517572e+24M → CGUD
9$3,356,370,330,330,650,300,000,000,000,000,000$3,353,903,924,103,914,000,000,000,000,000,000.00$24,792$3,191.91+$3.3563703303306504e+27M → CGUD
10$4,567,699,004,441,311,000,000,000,000,000,000,000$4,564,107,688,187,857,300,000,000,000,000,000,000.00$30,274$4,689.40+$4.567699004441311e+30M → CGUD

CGUD vs JNJ: Complete Analysis 2026

CGUD — Stock

Com-Guard.com, Inc. provides software products for security and tracker applications. The company offers ComputerSafe, which detects, protects, and reports various computer system security threats, including identity theft and firewall break-ins, as well as recovers lost or stolen computers. It also licensed Missed Call Tracker software for loyalty programs for tracking member activities and payments. In addition, the company holds licenses for the Cash Engine Software. It has distribution and licensing agreements for North America, including Canada, Mexico, and the Caribbean with The Company USA PTY, Ltd. The company was formerly known as e-World Security, Inc. and changed its name to Com-Guard.com, Inc. in April 1999. Com-Guard.com, Inc. was incorporated in 1998 and is based in Encinitas, California.

Full CGUD Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CGUD vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CGUD vs SCHDCGUD vs JEPICGUD vs OCGUD vs KOCGUD vs MAINCGUD vs ABBVCGUD vs MRKCGUD vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.